Brief: Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Jan 12 (Reuters) - CK Life Sciences Intl (Holdings) Inc 0775.HK: DOGWOOD THERAPEUTICS, INC. ANNOUNCES FINANCING OF UP TO $26.8 MILLION TO PROGRESS HALNEURON® THROUGH PHASE 2B DEVELOPMENT Source text: ID:nGNX3CkQW1 Further company coverage: 0775.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CK Life Sciences Intl (Holdings)
See all newsCK Life Sciences H1 loss narrows on lower R&D costs
Brief: CK Life Sciences Intl Announces Resignation Of Lance Richard Lee Yuen As Executive Director, CEO
Brief: CK Life Sciences Intl Logs FY Loss Attributable HK$186.8 Mln
CK Life Sciences rises most in 4 months on advancing cancer vaccine development
Brief: CK Life Sciences Intl Establishes Sequencio Therapeutics For Cancer Vaccine Development